share_log

CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital International Investors(10.2%)

CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

CRISPR Therapeutics | SC 13G/A：超過5%持股股東披露文件(修正)
SEC announcement ·  04/11 00:02
牛牛AI助理已提取核心訊息
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission on March 29, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing reveals that CII now beneficially owns 8,223,994 shares of CRISPR Therapeutics' common stock, which represents 10.2% of the company's total outstanding shares. This position is held solely by CII, with no shared voting or dispositive power reported. The address of CII's principal business office is located at 333 South Hope Street, 55th Floor, Los Angeles, CA 90071. The filing was certified by Jae Won Chung, Vice President and Associate Counsel of the Fund Business Management Group at Capital Research and Management Company, on April 10, 2024. The statement asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission on March 29, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing reveals that CII now beneficially owns 8,223,994 shares of CRISPR Therapeutics' common stock, which represents 10.2% of the company's total outstanding shares. This position is held solely by CII, with no shared voting or dispositive power reported. The address of CII's principal business office is located at 333 South Hope Street, 55th Floor, Los Angeles, CA 90071. The filing was certified by Jae Won Chung, Vice President and Associate Counsel of the Fund Business Management Group at Capital Research and Management Company, on April 10, 2024. The statement asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
資本研究與管理公司旗下的資本國際投資者（CII）已於2024年3月29日向美國證券交易委員會提交了其附表13G的修正案，表明CRISPR Therapeutics AG擁有大量所有權。該文件顯示，CII現在實益擁有CRISPR Therapeutics普通股的8,223,994股，佔該公司已發行股票總額的10.2％。該職位僅由CII擔任，未報告共享投票權或決定權。CII主要業務辦公室的地址位於加利福尼亞州洛杉磯南希望街333號55樓 90071。該文件於2024年4月10日由資本研究與管理公司基金業務管理組副總裁兼助理法律顧問Jae Won Chung認證。該聲明稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響CRISPR Therapeutics的控制權。
資本研究與管理公司旗下的資本國際投資者（CII）已於2024年3月29日向美國證券交易委員會提交了其附表13G的修正案，表明CRISPR Therapeutics AG擁有大量所有權。該文件顯示，CII現在實益擁有CRISPR Therapeutics普通股的8,223,994股，佔該公司已發行股票總額的10.2％。該職位僅由CII擔任，未報告共享投票權或決定權。CII主要業務辦公室的地址位於加利福尼亞州洛杉磯南希望街333號55樓 90071。該文件於2024年4月10日由資本研究與管理公司基金業務管理組副總裁兼助理法律顧問Jae Won Chung認證。該聲明稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響CRISPR Therapeutics的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。